Participated · Series A · Jul 2025

Q.ANT is building photonic AI infrastructure, a technology stack that leverages photonics to accelerate artificial intelligence workloads. The company focuses on integrating quantum-inspired photonics with AI processing to increase computational speed and energy efficiency. Its platform aims to serve research institutions and commercial customers requiring high-performance AI capabilities. Q.ANT recently added $80 million through a second Series A tranche, underscoring investor confidence in its technology roadmap. The infusion of capital will support further product development and potential scaling of manufacturing capacity. Specific operating metrics such as revenue, user base, or customer count were not disclosed in the article.

Participated · Series A · Mar 2024

Threedy offers instant3Dhub, a high-performance spatial computing technology platform that enables customers to use 3D data, any compositions, and visualize them at scale. The platform makes data available and accessible in real time on any device, allowing companies to optimize digital processes across the industrial value chain. Threedy says this capability helps reduce associated costs and waiting times for industrial workflows. The company intends to use the new funding to accelerate growth across industries and regions. Threedy is based in Darmstadt, Germany and focuses on applying its spatial computing technology across industrial use cases. Threedy offers an instant3Dhub platform that enables high-performance visual computing and the use of data sets of any size across application and device classes. The platform connects directly with business data and sensors and is built to support visualization, virtual reality (VR) and augmented reality (AR) applications. Initial commercial focus is on companies in the automotive, aerospace and energy industries, as well as users of building information modeling (BIM) solutions. The startup is a spin-off from the Fraunhofer Institute for Computer Graphics Research IGD in Darmstadt, Germany. The company intends to use the seed funding to commercialize its platform. No operating metrics were disclosed in the article.

Participated · Equity · Jul 2023

Quside builds quantum randomness solutions—QRNG devices and a randomness processing unit (RPU)—for cybersecurity and high-performance computing customers. The company recently upgraded its QRNG line to a 1 gigabit-per-second rate and launched its RPU on Amazon Web Services to ease corporate adoption. Founded in 2017 and based in Barcelona, Quside employs roughly 42–45 people. The capital from the funding round will support internationalization, scale its product range and production capacity, and accelerate sales and marketing. Quside plans to hire specialists in quantum systems engineering, semiconductor chips, FPGA and software development, as well as commercial profiles. It already works with partners and customers such as EY, Telefónica, Juniper and Qrypt.

Led · Equity · Dec 2022

iThera Medical, based in Munich, develops and markets Multispectral Optoacoustic Tomography (MSOT) imaging systems that use the photoacoustic effect to convert light into sound waves and visualize optical contrast at high resolution in deep tissue. The company’s MSOT technology is used for preclinical and clinical research and is already deployed at leading academic hospitals worldwide. Led by CEO Christian Wiest, iThera has focused on demonstrating MSOT’s clinical potential across a variety of disease areas. The company closed a €13M financing to support its next stage of development. Proceeds will be used to develop a MSOT device optimized for routine clinical use, to pursue CE and FDA regulatory approvals, and to expand clinical evidence in priority clinical indications. The financing included new and existing investors to accelerate the company’s transition from research deployments toward regulated clinical applications. iThera Medical is a spin-off from the Helmholtz Zentrum München that develops and markets multispectral optoacoustic tomography (MSOT), a non-invasive imaging technology providing real-time anatomical, functional and molecular information in living tissue. MSOT was invented by Prof. Vasilis Ntziachristos and Dr. Daniel Razansky at Helmholtz Zentrum München and is positioned for preclinical drug-discovery validation across oncology, neurology and cardiovascular indications, with future potential in clinical diagnostics. The company plans to use the recent funds to further develop and commercialize the technology for both preclinical and clinical applications. Earlier this year iThera secured a Phase II grant from the GO‑Bio programme (funded by the German Ministry of Education and Research, BMBF, and managed by Projektträger Jülich). Ascenion, the Helmholtz Zentrum’s technology transfer partner, supported the company’s foundation and funding and holds equity. The company is led by co‑founder and CEO Christian Wiest.

Participated · Series B · Dec 2022

Resistell has developed a diagnostic device and rapid AST method based on detecting vibrations from living bacterial cells, enabling growth-independent results in hours rather than days. Its R&D device is named Phenotech Research. Clinical validation is underway: the first clinical study for bacteremia and sepsis at the University Hospital in Lausanne is halfway through and shows a large reduction in time to result and around 95% accuracy versus the gold standard. A second multi-site study with three European hospitals has just started. The company intends to use new funds to complete clinical trials and bring Phenotech Research to market. It plans to seek IVDR certification and to commercialize first in the research market while pursuing partnerships with the diagnostic industry, medical centers, and academia. Resistell develops a rapid phenotypic antibiotic susceptibility test that measures movements of living bacteria via nanotechnology and Atomic Force Microscopy to determine antibiotic effectiveness in hours rather than days. The method detects cessation of bacterial motion when an effective antibiotic is applied, enabling correct treatment from day one. The technology was researched at EPFL since 2012 by a team of physicists, physicians and microbiologists led by inventors Prof. Giovanni Dietler and Dr. Sandor Kasas, and the company achieved a proof-of-concept, a 3rd-generation prototype and successful tests on samples from University Hospital in Lausanne (CHUV). A European patent for the device and method was granted in summer 2018, and Resistell was incorporated in April 2018 in Basel; it is moving to new premises in Muttenz. The company aims to become the gold standard in phenotypic antibiotic susceptibility testing and is testing devices in a dedicated AFM laboratory at CHUV with Prof. Gilbert Greub as Chief Scientific Advisor. Management and board additions include CEO Danuta Cichocka, Derek Brandt and Michal Bartos joining the Board, and the startup has support from Venture Kick.